Objective To investigate expression level of interleukin-27 (IL-27)and its impact on virus replication in lung after infected with respiratory syncytial virus (RSV). Methods In vivo,7-week aged female C57 mice were infected with RSV and sacrificed on day 0,0.5,1,2,4,6,8 (n=5).The left lung was extracted for RNA,and then real-time PCR was used to detect the mRNA levels of IL-27p28,IL-27EBI3, RSV-M protein and interferon-β (IFN-β).The right lung was used for HE staining.In vitro, human lung epithelial cells (A549)were infected with RSV,and stimulated with different concentrations of recombinant human interleukin 27 (rhIL-27)in doses of 0,1ng/mL,10ng/mL,and 50ng/mL.After 24 hours,the mRNA expression of interferon induced transmembrane protein 3 (IFITM3),IFN-β,and RSV-M protein were determined by real-time PCR.IFITM3 and STAT1/pSTAT1 protein expression levels were detected by Western blot. Results The viral load in the lungs of mice peaked on 4 day post infection (DPI),then gradually decreased,and almost returned to normal on 8 DPI.IFN-β increased transiently 12 hours after infection,and then quickly returned to normal baseline.IL-27 p28/EBI3 levels peaked on 1 DPI,then gradually decreased to normal on 4 DPI.Stimulating RSV-infected A549 cells with rhIL-27 of 10ng/mL and 50ng/mL significantly inhibited viral replication,enhanced IFTIM3 mRNA expression,and induced STAT1 phosphorylation.However,rhIL-27 stimulation did not affect IFN-β mRNA expression. Conclusions The IL-27 mRNA expression increases after RSV infection.The inhibition of IL-27 on RSV replication might be related to up-regulation of STAT1 phosphorylation and IFITM3 protein expression.
ObjectiveTo systematically review the correlation of pSTAT3 overexpression and prognosis in lung cancer patients.MethodsWe searched from PubMed, EMbase, Web of Science, CNKI, VIP and WanFang Data databases to collect relevant studies about the correlation of pSTAT3 overexpression and prognosis in lung cancer patients from inception to November 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.2 software.Results A total of thirteen studies were enrolled. The results of the meta-analysis showed that the overall survival (HR=1.23, 95%CI 1.04 to 1.46, P=0.02) of pSTAT3 overexpression group was shorter than that of low expression group. In terms of clinical prognostic characteristics, pSTAT3 overexpression rate in stage Ⅲ to Ⅳ group was significantly higher than stage Ⅰ to Ⅱ (OR=1.92, 95%CI 1.13 to 3.27, P=0.02). pSTAT3 overexpression rate of lung cancer patients with lymphatic node metastasis was also significantly higher than lung cancer patients without lymphatic node metastasis (OR=1.81, 95%CI 1.20 to 2.72, P=0.004). However, there was no statistical difference of pSTAT3 overexpression between well-moderately differentiation and poorly differentiation group (OR=0.82, 95%CI 0.44 to 1.53, P=0.54).ConclusionpSTAT3 overexpression is associated with poorer overall survival of lung cancer patients, as well as with more and advanced TNM grade and lymph node metastasis. It may be an indicator poor biomarker in lung cancer patients. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion.